T3D Therapeutics, Inc.

CymaBay Therapeutics Inc. already had revised the development strategy for its PPAR delta agonist seladelpar in non-alcoholic steatohepatitis (NASH) following disappointing liver fat-reduction readin

Venture capital investment in biopharmaceutical companies has been on the decline in 2019, but one segment of the industry has seen a big rise in VC funding – cell and gene therapy companies. A recent

Industry executives and biopharmaceutical analysts are reluctant to say that the failure of Eli Lilly & Co. ’s solanezumab in a third Phase III clinical trial is the end of the road for the amyloid

IN VITRO DIAGNOSTICS Mergers & Acquisitions Analytik Jena AG SIRS-Lab GMBH Life sciences firm Analytik Jena AG has acquired all of the assets of insolvent molecular diagnostics firm SIRS-Lab GMB